What is the drug of choice for malignant hyperthermia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dantrolene is the Drug of Choice for Malignant Hyperthermia

Dantrolene sodium is unequivocally the drug of choice for treating malignant hyperthermia (MH), with an initial dose of 2-2.5 mg/kg administered intravenously, repeated every 10 minutes until signs of MH regress 1.

Dosing Algorithm

The treatment protocol follows this specific sequence:

  • Initial bolus: 2-2.5 mg/kg IV (based on actual body weight, not ideal body weight, up to maximum initial dose of 300 mg) 1
  • Repeat dosing: Give 2-2.5 mg/kg every 10 minutes (or as often as possible if administration takes >10 minutes) until MH signs regress 1
  • Stop criteria: PaCO₂ < 6 kPa with normal minute ventilation AND decreasing core body temperature 1
  • Maximum dose: The recommended 10 mg/kg maximum may need to be exceeded in fulminant reactions 1

Post-Crisis Management

After initial resolution with loading dose:

  • Do NOT routinely use continuous dantrolene infusion - therapeutic plasma concentrations are maintained for ~6 hours after loading dose, and infusion causes thrombophlebitis and dose-dependent muscle weakness that may compromise ventilation 1
  • If recrudescence occurs: Administer further doses of 2-2.5 mg/kg every 10 minutes until signs regress again 1

Evidence Strength

The superiority of dantrolene is supported by multiple lines of evidence. The 2020 European Malignant Hyperthermia Group guidelines provide the strongest contemporary evidence, establishing dantrolene as essential in treating fulminant MH 1. Historical comparative studies demonstrated dantrolene's effectiveness versus alternatives like procainamide, which showed no effect on MH muscle contractures at clinical doses 2. A multicenter study of 21 patients showed that when dantrolene was administered promptly according to protocol, all 11 patients with unequivocal or probable MH recovered without sequelae, whereas delayed treatment (>24 hours) resulted in 75% mortality 3.

Critical Institutional Requirements

Every institution using MH trigger drugs must have a plan to deliver the initial 2-2.5 mg/kg bolus within 5 minutes of MH diagnosis 1. For locations regularly using triggering agents, stock 36 vials immediately available (48 vials if additional dantrolene cannot be obtained within 30 minutes, 60 vials if cannot be obtained within 1 hour) 1.

Common Pitfall

The most important caveat: dantrolene is hepatotoxic and prolonged use is not recommended in active hepatic disease 4. However, low-dose dantrolene has been used successfully even during liver transplantation without affecting allograft recovery 4, so acute MH treatment should not be withheld even in severe liver disease given the life-threatening nature of untreated MH.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.